CN111065639A - 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 - Google Patents

一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 Download PDF

Info

Publication number
CN111065639A
CN111065639A CN201980001562.9A CN201980001562A CN111065639A CN 111065639 A CN111065639 A CN 111065639A CN 201980001562 A CN201980001562 A CN 201980001562A CN 111065639 A CN111065639 A CN 111065639A
Authority
CN
China
Prior art keywords
compound
amino
methyl
preparation
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980001562.9A
Other languages
English (en)
Other versions
CN111065639B (zh
Inventor
陈小华
李佳
冯序乐
周宇波
田洪涛
张凯祥
王培培
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CN111065639A publication Critical patent/CN111065639A/zh
Application granted granted Critical
Publication of CN111065639B publication Critical patent/CN111065639B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

公开了通式(I)所示的靶向细胞周期依赖性激酶(CDKs)降解剂的化合物和/或其药学上可接受的盐、其药物组合物以及这些衍生物作为药物活性剂，用于预防和/或治疗CDKs异常活性相关的疾病的药物中的用途。所述化合物对实体肿瘤和血液肿瘤均具有较好的抑制细胞增殖的效果，说明具有潜在的治疗相关癌症和自身免疫性疾病的潜力。
Figure DDA0002335021320000011

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201980001562.9A 2018-08-17 2019-08-16 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 Active CN111065639B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018109432511 2018-08-17
CN201810943251.1A CN110835345A (zh) 2018-08-17 2018-08-17 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
PCT/CN2019/100969 WO2020035049A1 (zh) 2018-08-17 2019-08-16 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途

Publications (2)

Publication Number Publication Date
CN111065639A true CN111065639A (zh) 2020-04-24
CN111065639B CN111065639B (zh) 2023-03-10

Family

ID=69525215

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810943251.1A Pending CN110835345A (zh) 2018-08-17 2018-08-17 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
CN201980001562.9A Active CN111065639B (zh) 2018-08-17 2019-08-16 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810943251.1A Pending CN110835345A (zh) 2018-08-17 2018-08-17 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途

Country Status (2)

Country Link
CN (2) CN110835345A (zh)
WO (1) WO2020035049A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113402520A (zh) * 2020-03-16 2021-09-17 中国科学院上海药物研究所 Wee1蛋白降解剂
CN114133394B (zh) * 2020-08-12 2023-12-08 赛诺哈勃药业（成都）有限公司 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途
CN114349738B (zh) * 2020-10-14 2023-05-05 清华大学 一类靶向降解cdk2的小分子缀合物及其应用
WO2022248682A1 (en) * 2021-05-28 2022-12-01 Qurient Co., Ltd. Compounds for degradation of cyclin-dependent kinase 7 (cdk7)
CN115521313B (zh) * 2021-06-24 2023-11-03 山东大学 一种降解btk蛋白的化合物及其制备方法和应用
CN116396298A (zh) * 2023-06-06 2023-07-07 四川维亚本苑生物科技有限公司 CDK Ligand-1的中间体XII及CDK Ligand-1的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1575286A (zh) * 2001-10-25 2005-02-02 伊莱利利公司 用作抗肿瘤剂的噻吩和噻唑磺酰胺化合物
WO2012078492A1 (en) * 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
WO2014063061A1 (en) * 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2015154022A1 (en) * 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107530329A (zh) * 2015-03-09 2018-01-02 奥瑞基尼探索技术有限公司 用作CDK抑制剂的吡唑并[1,5‑a][1,3,5]三嗪和吡唑并[1,5‑a]嘧啶衍生物
WO2018106870A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
WO2018119441A1 (en) * 2016-12-23 2018-06-28 Arvinas, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1575286A (zh) * 2001-10-25 2005-02-02 伊莱利利公司 用作抗肿瘤剂的噻吩和噻唑磺酰胺化合物
WO2012078492A1 (en) * 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
WO2014063061A1 (en) * 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2015154022A1 (en) * 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107530329A (zh) * 2015-03-09 2018-01-02 奥瑞基尼探索技术有限公司 用作CDK抑制剂的吡唑并[1,5‑a][1,3,5]三嗪和吡唑并[1,5‑a]嘧啶衍生物
WO2018106870A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
WO2018119441A1 (en) * 2016-12-23 2018-06-28 Arvinas, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAUREEN CALIGIURI，等: "MASPIT: Three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells", 《CHEMISTRY & BIOLOGY》 *

Also Published As

Publication number Publication date
CN111065639B (zh) 2023-03-10
CN110835345A (zh) 2020-02-25
WO2020035049A1 (zh) 2020-02-20

Similar Documents

Publication Publication Date Title
CN111065639B (zh) 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
KR102548191B1 (ko) 표적 단백질 분해 화합물, 이의 항종양 응용, 이의 중간체 및 중간체의 응용
EP3381896B1 (en) Biphenyl compound or salt thereof
EP2964222B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
IL262345A (en) Inhibitors of the kinase-like activin receptor
EP2556070B1 (en) Synthesis of chiral 2-(1h-indazol-6-yl)-spiro[cyclopropane-1,3'- indolin]-2'-ones
EP3684776B1 (en) Heterocyclyl substituted pyrrolopyridines that are inhibitors of the cdk12 kinase
CN114040914A (zh) 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
CN113286794A (zh) Kras突变蛋白抑制剂
CN109496213B (zh) 螺环化合物及其制备和使用方法
EP4212522A1 (en) Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof
HUE032470T2 (en) Morphinan derivative
CN107531714A (zh) 作为pde1抑制剂的咪唑并吡嗪酮
BR112021011147A2 (pt) Benzamidas de derivados de pirazolil-amino-pirimidinila e composições e métodos das mesmas
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
US20110059982A1 (en) Azaindole compounds for treatment of central nervous system disorders
CN115413279A (zh) P2x3调节剂
CN116323625A (zh) 杂环类衍生物、其制备方法及其医药上的用途
JP7338896B2 (ja) Ｍｄｍ２阻害剤、その調製方法、医薬組成物および応用
JP2023516102A (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物、およびそれを含む医薬組成物
IE902786A1 (en) 1-(Pyridinylamino)-2-pyrrolidinones, a process for their preparation and their use as medicaments
CN114805361B (zh) 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途
EP4206197A1 (en) Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method
KR20240019071A (ko) N2-페닐피리미딘-2,4-디아민 화합물, 및 그 제조 방법 및 사용 방법
WO1999003833A1 (en) Piperazine derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant